{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "11728816", "DateCompleted": {"Year": "2002", "Month": "02", "Day": "08"}, "DateRevised": {"Year": "2019", "Month": "08", "Day": "26"}, "Article": {"Language": ["eng"], "ELocationID": [], "ArticleDate": [], "Journal": {"ISSN": "0891-5849", "JournalIssue": {"Volume": "31", "Issue": "11", "PubDate": {"Year": "2001", "Month": "Dec", "Day": "01"}}, "Title": "Free radical biology & medicine", "ISOAbbreviation": "Free Radic Biol Med"}, "ArticleTitle": "Effect of apocynin on ozone-induced airway hyperresponsiveness to methacholine in asthmatics.", "Pagination": {"StartPage": "1442", "EndPage": "1447", "MedlinePgn": "1442-7"}, "Abstract": {"AbstractText": ["Apocynin is an inhibitor of NADPH oxidase present in inflammatory cells such as eosinophils and neutrophils. We investigated the effect of inhaled apocynin on ozone-induced bronchial hyperresponsiveness in vivo. Seven mild atopic asthmatics participated in a placebo-controlled, cross-over study with two exposures to O(3) at 2-week intervals. Apocynin (3 ml of 0.5 mg/ml) was inhaled 2 times before and 6 times after O(3) exposure at hourly intervals. At 36 h before and 16 h after O(3) exposure, methacholine inhalation challenge tests (Mch) were performed, and PC(20) and maximal % fall from baseline (MFEV(1)) were calculated from dose-response curves. O(3)-induced change in PC(20) (Delta PC(20)) after placebo treatment was -1.94 +/- 0.39 DD (mean +/- SEM doubling dose Mch) (p =.001) and apocynin was -0.6 +/- 0.33 DD (p =.17). The difference between apocynin and placebo treatment was 1.3 DD +/- 0.42 (p =.02). O(3)-induced Delta MFEV(1) was 11.9 +/- 1.5% (p =.008) during placebo inhalation and 3.85 +/- 1.8% during apocynin (p =.47). Apocynin reduced the Delta MFEV(1) by 8.05% compared to placebo (p =.025). We conclude that apocynin markedly reduced O(3)-induced hyperreactivity for Mch as well as maximal airway narrowing. The results suggest that apocynin may have a role in preventing ozone-induced exacerbations of asthma."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pulmonology, Leiden University Medical Center, The, Leiden, Netherlands."}], "Identifier": [], "LastName": "Peters", "ForeName": "E A", "Initials": "EA"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Hiltermann", "ForeName": "J T", "Initials": "JT"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Stolk", "ForeName": "J", "Initials": "J"}], "PublicationTypeList": ["Clinical Trial", "Controlled Clinical Trial", "Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Free Radic Biol Med", "NlmUniqueID": "8709159", "ISSNLinking": "0891-5849"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Acetophenones"}, {"RegistryNumber": "0", "NameOfSubstance": "Aerosols"}, {"RegistryNumber": "0", "NameOfSubstance": "Antioxidants"}, {"RegistryNumber": "0", "NameOfSubstance": "Bronchoconstrictor Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Enzyme Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Placebos"}, {"RegistryNumber": "0W5ETF9M2K", "NameOfSubstance": "Methacholine Chloride"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "B6J7B9UDTR", "NameOfSubstance": "acetovanillone"}, {"RegistryNumber": "EC 1.6.3.-", "NameOfSubstance": "NADPH Oxidases"}], "MeshHeadingList": [{"QualifierName": ["administration & dosage", "therapeutic use"], "DescriptorName": "Acetophenones"}, {"QualifierName": [], "DescriptorName": "Administration, Inhalation"}, {"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Aerosols"}, {"QualifierName": ["administration & dosage", "therapeutic use"], "DescriptorName": "Antioxidants"}, {"QualifierName": ["physiopathology"], "DescriptorName": "Asthma"}, {"QualifierName": ["chemically induced", "prevention & control"], "DescriptorName": "Bronchial Hyperreactivity"}, {"QualifierName": [], "DescriptorName": "Bronchial Provocation Tests"}, {"QualifierName": ["administration & dosage"], "DescriptorName": "Bronchoconstrictor Agents"}, {"QualifierName": [], "DescriptorName": "Cross-Over Studies"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": [], "DescriptorName": "Double-Blind Method"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Enzyme Inhibitors"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Forced Expiratory Volume"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["administration & dosage"], "DescriptorName": "Methacholine Chloride"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "NADPH Oxidases"}, {"QualifierName": [], "DescriptorName": "Ozone"}, {"QualifierName": [], "DescriptorName": "Placebos"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2001", "Month": "12", "Day": "1", "Hour": "10", "Minute": "0"}, {"Year": "2002", "Month": "2", "Day": "9", "Hour": "10", "Minute": "1"}, {"Year": "2001", "Month": "12", "Day": "1", "Hour": "10", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["11728816", "10.1016/s0891-5849(01)00725-0", "S0891584901007250"]}}], "PubmedBookArticle": []}